Resolvins and aliamides: lipid autacoids in ophthalmology – what promise do they hold?
Received 9 May 2016
Accepted for publication 7 July 2016
Published 27 September 2016 Volume 2016:10 Pages 3133—3141
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Palas Chanda
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Frank Boeckler
Jan M Keppel Hesselink,1 Flavia Chiosi,2 Ciro Costagliola2
1University of Witten/Herdecke, Witten, Germany; 2Eye Clinic, Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy
Abstract: Resolvins are a novel class of lipid-derived endogenous molecules (autacoids) with potent immunomodulating properties, which regulate the resolution phase of an active immune response. These modulating factors are locally produced, influencing the function of cells and/or tissues, which are produced on demand and subsequently metabolized in the same cells and/or tissues. This review is focused on certain lipid autacoids with putative relevance for ophthalmology in general and for dry eye more specifically. We also briefly investigate the concept of aliamides and the role of palmitoylethanolamide in ophthalmology, and analyze in more detail the putative role and the preclinical and clinical development of resolvins as emerging treatments for dry eye and related disorders, with a focus on one of the lead resolvin derivatives – RX-10045.
Keywords: resolvins, autacoids, aliamides, dry eye, palmitoylethanolamide, inflammation, ophthalmology, protection
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]